GIORDANO, SILVIA
GIORDANO, SILVIA
SCIENZE MEDICHE
Extensive "halo naevi" phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome?
2022-01-01 Cavallo, Francesco; Roccuzzo, Gabriele; Avallone, Gianluca; Conforti, Claudio; Zalaudek, Iris; Giordano, Silvia; Rubatto, Marco; Fava, Paolo; Ribero, Simone; Quaglino, Pietro
Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks
2022-01-01 Mastorino, L; Cantafio Duò, V L; Vecco, C; Gelato, F; Giordano, S; Roccuzzo, G; Cavaliere, G; Avallone, G; Ortoncelli, M; Ribero, S; Quaglino, P
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
2022-01-01 Berrino, Enrico; Annaratone, Laura; Bellomo, Sara Erika; Ferrero, Giulio; Gagliardi, Amedeo; Bragoni, Alberto; Grassini, Dora; Guarrera, Simonetta; Parlato, Caterina; Casorzo, Laura; Panero, Mara; Sarotto, Ivana; Giordano, Silvia; Cereda, Matteo; Montemurro, Filippo; Ponzone, Riccardo; Crosetto, Nicola; Naccarati, Alessio; Sapino, Anna; Marchiò, Caterina
Nonmelanoma skin cancer arising on tattoos
2022-01-01 Rubatto, Marco; Gelato, Federica; Mastorino, Luca; Giordano, Silvia; Ribero, Simone; Quaglino, Pietro
Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center
2023-01-01 Roccuzzo, Gabriele; Giordano, Silvia; Granato, Thomas; Cavallo, Francesco; Mastorino, Luca; Avallone, Gianluca; Pasini, Barbara; Quaglino, Pietro; Ribero, Simone
Reply to ‘The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?’ by Damiani G et al
2022-01-01 Avallone G.; Giordano S.; Astrua C.; Merli M.; Senetta R.; Conforti C.; Ribero S.; Marzano A.V.; Quaglino P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Extensive "halo naevi" phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome? | 2022 | Cavallo, Francesco; Roccuzzo, Gabriele; Avallone, Gianluca; Conforti, Claudio; Zalaudek, Iris; Giordano, Silvia; Rubatto, Marco; Fava, Paolo; Ribero, Simone; Quaglino, Pietro | |
| Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks | 2022 | Mastorino, L; Cantafio Duò, V L; Vecco, C; Gelato, F; Giordano, S; Roccuzzo, G; Cavaliere, G; Avallone, G; Ortoncelli, M; Ribero, S; Quaglino, P | |
| Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas | 2022 | Berrino, Enrico; Annaratone, Laura; Bellomo, Sara Erika; Ferrero, Giulio; Gagliardi, Amedeo; Bragoni, Alberto; Grassini, Dora; Guarrera, Simonetta; Parlato, Caterina; Casorzo, Laura; Panero, Mara; Sarotto, Ivana; Giordano, Silvia; Cereda, Matteo; Montemurro, Filippo; Ponzone, Riccardo; Crosetto, Nicola; Naccarati, Alessio; Sapino, Anna; Marchiò, Caterina | |
| Nonmelanoma skin cancer arising on tattoos | 2022 | Rubatto, Marco; Gelato, Federica; Mastorino, Luca; Giordano, Silvia; Ribero, Simone; Quaglino, Pietro | |
| Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center | 2023 | Roccuzzo, Gabriele; Giordano, Silvia; Granato, Thomas; Cavallo, Francesco; Mastorino, Luca; Avallone, Gianluca; Pasini, Barbara; Quaglino, Pietro; Ribero, Simone | |
| Reply to ‘The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?’ by Damiani G et al | 2022 | Avallone G.; Giordano S.; Astrua C.; Merli M.; Senetta R.; Conforti C.; Ribero S.; Marzano A.V.; Quaglino P. |